Non-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis process involving various genetic and epigenetic alterations, which essentially contribute to the high incidence of mortality among patients with NSCLC. Clinical observations revealed that NSCLC also co-opts a multifaceted immune checkpoint dysregulation as an important driving factor in NSCLC progression and development. For example, a deregulated PI3K/AKT/mTOR pathway has been noticed in 50-70% of NSCLC cases, primarily modulated by mutations in key oncogenes such as ALK, EGFR, KRAS, and others. Additionally, genetic association studies containing patient-specific factors and local reimbursement criteria expose/reveal mutations in EGFR/ALK/ROS/BRAF/KRAS/PD-L1 proteins to determine the suitability of available immunotherapy or tyrosine kinase inhibitor therapy. Thus, the expression of such checkpoints on tumors and immune cells is pivotal in understanding the therapeutic efficacy and has been extensively studied for NSCLC treatments. Therefore, this review summarizes current knowledge in NSCLC tumorigenesis, focusing on its genetic and epigenetic intricacies, immune checkpoint dysregulation, and the evolving landscape of targeted therapies. In the context of current and future therapies, we emphasize the significance of antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as the primary therapeutic strategy for immune system reactivation in NSCLC. Other approaches involving the promising potential of nanobodies, probodies, affibodies, and DARPINs targeting immune checkpoints are also described; these are under active research or clinical trials to mediate immune regulation and reduce cancer progression. This comprehensive review underscores the multifaceted nature, current state and future directions of NSCLC research and treatment.

Department of Immunology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czechia

Department of Immunology University Hospital Olomouc Olomouc Czechia

Department of Pathology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czechia

Department of Respiratory Diseases and Tuberculosis University Hospital Olomouc Olomouc Czechia

Institute of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czechia

Laboratory of Ligand Engineering Institute of Biotechnology of the Czech Academy of Sciences Vestec Czechia

Zobrazit více v PubMed

Malvezzi M, Santucci C, Boffetta P, Collatuzzo G, Levi F, La Vecchia C, et al. . European cancer mortality predictions for the year 2023 with focus on lung cancer. Ann Oncol (2023) 34:410–9. doi: 10.1016/j.annonc.2023.01.010. PubMed DOI

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin (2023)73:17–48. doi: 10.3322/caac.21763. PubMed DOI

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. . Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network (2017) 15:504–35. doi: 10.6004/jnccn.2017.0050. PubMed DOI

Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. . Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol (2015) 3:217–21. doi: 10.3892/mco.2014.410. PubMed DOI PMC

Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer (2007) 57:253–60. doi: 10.1016/j.lungcan.2007.03.012. PubMed DOI

Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 8:329–40. doi: 10.1038/nrc2375. PubMed DOI

Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol (1993) 143:1713–23. PubMed PMC

Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res (2014) 133 Suppl 2:S149–57. doi: 10.1016/S0049-3848(14)50025-4. PubMed DOI

D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. . Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 6:101–14. doi: 10.1177/1758834014521110. PubMed DOI PMC

Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res (2015) 35:5797–806. PubMed

Choi MG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, et al. . Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res (2021) 10:2551–61. doi: 10.21037/tlcr. PubMed DOI PMC

Yang K, Li J, Bai C, Sun Z, Zhao L. Efficacy of immune checkpoint inhibitors in non-small-cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis. Front Oncol (2020) 10:1098. doi: 10.3389/fonc.2020.01098. PubMed DOI PMC

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 17:1471–4. doi: 10.1245/s10434-010-0985-4. PubMed DOI

Detterbeck FC, Nishimura KK, Cilento VJ, Giuliani M, Marino M, Osarogiagbon RU, et al. . The international association for the study of lung cancer staging project: Methods and guiding principles for the development of the ninth edition TNM classification. J Thorac Oncol (2022) 17:806–15. doi: 10.1016/j.jtho.2022.02.008. PubMed DOI

Non-small cell lung cancer treatment (PDQ®)–health professional version, national cancer institute. (2023). Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. PubMed

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2017) 28:iv1–iv21. doi: 10.1093/annonc/mdx222. PubMed DOI

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. . Osimertinib with or without Chemotherapy in. N Engl J Med (2023) 389:1935–48. doi: 10.1056/NEJMoa2306434. PubMed DOI

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. . Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med (2017) 377:829–38. doi: 10.1056/NEJMoa1704795. PubMed DOI

Süveg K, Plasswilm L, Iseli T, Leskow P, Fischer GF, Putora PM. Role of adjuvant radiotherapy in non-small cell lung cancer-A review. Cancers (Basel) (2022) 14(7):1617. doi: 10.3390/cancers14071617. PubMed DOI PMC

Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, et al. . Stage III non-small-cell lung cancer: An overview of treatment options. Curr Oncol (2023) 30:3160–75. doi: 10.3390/curroncol30030239. PubMed DOI PMC

Monteverdi S, Vita E, Sartori G, Ferrara MG, D'Argento E, Tortora G, et al. . Long-term survivors with immunotherapy in advanced NSCLC: Is 'cure' within reach? Transl Cancer Res (2020) 9:409–14. doi: 10.21037/tcr. PubMed DOI PMC

Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, et al. . Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer (2022) 128:778–87. doi: 10.1002/cncr.33984. PubMed DOI PMC

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. . Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 455:1069–75. doi: 10.1038/nature07423 PubMed DOI PMC

Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol (2012) 7:1315–26. doi: 10.1097/JTO.0b013e31825493eb. PubMed DOI

Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis (2013) 5 Suppl 5:S479–90. doi: 10.3978/j.issn.2072-1439.2013.08.03 PubMed DOI PMC

Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 6:184–92. doi: 10.1038/nrc1819. PubMed DOI

Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, et al. . Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol (2016) 11:545–55. doi: 10.1016/j.jtho.2015.12.107. PubMed DOI

Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. . EGFR exon 18 mutations in lung cancer: Molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res (2015) 21:5305–13. doi: 10.1158/1078-0432.CCR-15-1046. PubMed DOI

Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. . Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature (2021) 597:732–7. doi: 10.1038/s41586-021-03898-1. PubMed DOI PMC

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med (2018) 378:113–25. doi: 10.1056/NEJMoa1713137. PubMed DOI

Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 305:1163–7. doi: 10.1126/science.1101637. PubMed DOI

Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, et al. . Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res (2007) 67:2046–53. doi: 10.1158/0008-5472.CAN-06-3339. PubMed DOI

Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2010) 16:291–303. doi: 10.1158/1078-0432.CCR-09-1660. PubMed DOI

Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al. . Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res (2000) 6:2604–10. PubMed PMC

Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 241:353–7. doi: 10.1126/science.2838909. PubMed DOI PMC

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131:1190–203. doi: 10.1016/j.cell.2007.11.025. PubMed DOI

Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. . Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 15:5216–23. doi: 10.1158/1078-0432.CCR-09-0802. PubMed DOI PMC

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561–6. doi: 10.1038/nature05945. PubMed DOI

Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol (2016) 8:32–47. doi: 10.1177/1758834015617355. PubMed DOI PMC

Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA (2008) 105:20852–7. doi: 10.1073/pnas.0810958105. PubMed DOI PMC

Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell (2012) 150:12–27. doi: 10.1016/j.cell.2012.06.013. PubMed DOI

Wang Y, Zhang Y. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data. Sci Rep (2020) 10:8575. doi: 10.1038/s41598-020-65479-y. PubMed DOI PMC

Bravaccini S, Bronte G, Ulivi P. TMB in NSCLC: A broken dream? Int J Mol Sci (2021) 22(12):6536. doi: 10.3390/ijms22126536. PubMed DOI PMC

Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, et al. . Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood (2005) 105:2132–4. doi: 10.1182/blood-2004-01-0366. PubMed DOI

Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, Ziouta Y, et al. . High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res (2005) 65:10079–87. doi: 10.1158/0008-5472.CAN-05-1098. PubMed DOI

Safi S, Yamauchi Y, Rathinasamy A, Stamova S, Eichhorn M, Warth A, et al. . Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. Oncoimmunology (2017) 6:e1360458. doi: 10.1080/2162402X.2017.1360458. PubMed DOI PMC

Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. . Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol (2019) 12:93. doi: 10.1186/s13045-019-0787-5. PubMed DOI PMC

Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol (2019) 37:173–200. doi: 10.1146/annurev-immunol-042617-053402. PubMed DOI

Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, et al. . Identification of individual cancer-specific somatic mutations for neoantigen-based immunotherapy of lung cancer. J Thorac Oncol (2016) 11:324–33. doi: 10.1016/j.jtho.2015.11.006. PubMed DOI

Zhang W, Yin Q, Huang H, Lu J, Qin H, Chen S, et al. . Personal neoantigens from patients with NSCLC induce efficient antitumor responses. Front Oncol (2021) 11:628456. doi: 10.3389/fonc.2021.628456. PubMed DOI PMC

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. . Neoantigen-directed immune escape in lung cancer evolution. Nature (2019) 567:479–85. doi: 10.1038/s41586-019-1032-7. PubMed DOI PMC

Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. . Trastuzumab deruxtecan in patients with. J Clin Oncol (2023) 41:4852–63. doi: 10.1200/JCO.23.01361. PubMed DOI PMC

Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res (2013) 73:2381–8. doi: 10.1158/0008-5472.CAN-12-3932. PubMed DOI

Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, et al. . Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg (2009) 87:365–71; discussion 371-2. doi: 10.1016/j.athoracsur.2008.10.067. PubMed DOI

Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. . Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res (2011) 171:1–5. doi: 10.1016/j.jss.2011.03.068. PubMed DOI

O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol (2019) 16:151–67. doi: 10.1038/s41571-018-0142-8. PubMed DOI

Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer (2021) 21:526–36. doi: 10.1038/s41568-021-00366-w. PubMed DOI PMC

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science (2011) 331:1565–70. doi: 10.1126/science.1203486. PubMed DOI

Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 5:263–74. doi: 10.1038/nrc1586. PubMed DOI

Ohue Y, Nishikawa H, Regulatory T. (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci (2019) 110:2080–9. doi: 10.1111/cas.14069. PubMed DOI PMC

Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA (2008) 105:10113–8. doi: 10.1073/pnas.0711106105. PubMed DOI PMC

Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. . The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer (2010) 10:220. doi: 10.1186/1471-2407-10-220. PubMed DOI PMC

Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol (2015) 10:974–84. doi: 10.1097/JTO.0000000000000551. PubMed DOI PMC

Lucca LE, Dominguez-Villar M. Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nat Rev Immunol (2020) 20:680–93. doi: 10.1038/s41577-020-0296-3. PubMed DOI

Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, et al. . Regulatory T cells exhibit distinct features in human breast cancer. Immunity (2016) 45:1122–34. doi: 10.1016/j.immuni.2016.10.032. PubMed DOI PMC

Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. . Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell (2018) 174:1293–1308.e36. doi: 10.1016/j.cell.2018.05.060 PubMed DOI PMC

Munn DH, Mellor AL. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol (2016) 37:193–207. doi: 10.1016/j.it.2016.01.002. PubMed DOI PMC

Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol (2020) 58:313–25. doi: 10.1007/s12016-019-08753-w. PubMed DOI PMC

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, et al. . Immune cell composition in human non-small cell lung cancer. Front Immunol (2018) 9:3101. doi: 10.3389/fimmu.2018.03101. PubMed DOI PMC

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. . A transcriptionally and functionally distinct PD-1. Nat Med (2018) 24:994–1004. doi: 10.1038/s41591-018-0057-z. PubMed DOI PMC

Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 26:4410–7. doi: 10.1200/JCO.2007.15.0284. PubMed DOI

Müller E, Speth M, Christopoulos PF, Lunde A, Avdagic A, Øynebråten I, et al. . Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation. Front Immunol (2018) 9:2520. doi: 10.3389/fimmu.2018.02520. PubMed DOI PMC

Greene TT, Jo YR, Zuniga EI. Infection and cancer suppress pDC derived IFN-I. Curr Opin Immunol (2020) 66:114–22. doi: 10.1016/j.coi.2020.08.001. PubMed DOI PMC

Sautès-Fridman C, Verneau J, Sun CM, Moreira M, Chen TW, Meylan M, et al. . Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Semin Immunol (2020) 48:101406. doi: 10.1016/j.smim.2020.101406. PubMed DOI

Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol (2015) 6:67. doi: 10.3389/fimmu.2015.00067. PubMed DOI PMC

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. . B cells and tertiary lymphoid structures promote immunotherapy response. Nature (2020) 577:549–55. doi: 10.1038/s41586-019-1922-8 PubMed DOI PMC

Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. . Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature (2020) 577:561–5. doi: 10.1038/s41586-019-1914-8. PubMed DOI

Ren F, Xie M, Gao J, Wu C, Xu Y, Zang X, et al. . Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors. Cancer Med (2022) 11:2969–77. doi: 10.1002/cam4.4796. PubMed DOI PMC

Paulsen EE, Kilvaer T, Khanehkenari MR, Maurseth RJ, Al-Saad S, Hald SM, et al. . CD45RO(+) memory T lymphocytes–a candidate marker for TNM-immunoscore in squamous non-small cell lung cancer. Neoplasia (2015) 17:839–48. doi: 10.1016/j.neo.2015.11.004. PubMed DOI PMC

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res (2020) 10:727–42. PubMed PMC

Zhou C, Tang J, Sun H, Zheng X, Li Z, Sun T, et al. . PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget (2017) 8:58457–68. doi: 10.18632/oncotarget.v8i35. PubMed DOI PMC

Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B, Atallah JP. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Rev Anticancer Ther (2017) 17:47–59. doi: 1080/14737140.2017.1259574 PubMed

Zhang Y, Xiang C, Wang Y, Duan Y, Liu C. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget (2017) 8:101535–44. doi: 10.18632/oncotarget.v8i60. PubMed DOI PMC

Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114:1537–44. doi: 10.1182/blood-2008-12-195792. PubMed DOI PMC

Bally AP, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol (2016) 196:2431–7. doi: 10.4049/jimmunol.1502643. PubMed DOI PMC

Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 8:765–72. doi: 10.1093/intimm/8.5.765. PubMed DOI

Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med (2000) 191:891–8. doi: 10.1084/jem.191.5.891. PubMed DOI PMC

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther (2015) 14:847–56. doi: 10.1158/1535-7163.MCT-14-0983. PubMed DOI

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. . PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Clin Cancer Res (2017) 23:3158–67. doi: 10.1158/1078-0432.CCR-16-1761. PubMed DOI

Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol (2017) 8:961. doi: 10.3389/fimmu.2017.00961. PubMed DOI PMC

Böttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer (2018) 4:784–92. doi: 10.1016/j.trecan.2018.09.001. PubMed DOI PMC

Mansour MSI, Malmros K, Mager U, Ericson Lindquist K, Hejny K, Holmgren B, et al. . PD-L1 expression in non-small cell lung cancer specimens: Association with clinicopathological factors and molecular alterations. Int J Mol Sci (2022) 23(9):4517. doi: 10.3390/ijms23094517. PubMed DOI PMC

Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, et al. . PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med (2015) 13:5. doi: 10.1186/s12967-014-0373-0. PubMed DOI PMC

Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol (2016) 27:409–16. doi: 10.1093/annonc/mdv615. PubMed DOI

Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van Scheltinga AG, et al. . MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol (2019) 249:52–64. doi: 10.1002/path.5280. PubMed DOI PMC

Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell (2019) 76:359–70. doi: 10.1016/j.molcel.2019.09.030. PubMed DOI PMC

Dang CV. MYC on the path to cancer. Cell (2012) 149:22–35. doi: 10.1016/j.cell.2012.03.003. PubMed DOI PMC

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. . MYC regulates the antitumor immune response through CD47 and PD-L1. Science (2016) 352:227–31. doi: 10.1126/science.aac9935. PubMed DOI PMC

Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. . DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun (2017) 8:1751. doi: 10.1038/s41467-017-01883-9. PubMed DOI PMC

Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, et al. . PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol (2017) 22:1026–33. doi: 10.1007/s10147-017-1161-7. PubMed DOI

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, et al. . Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci USA (2018) 115:E10119–26. doi: 10.1073/pnas.1802166115. PubMed DOI PMC

Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, et al. . PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol (2016) 11:62–71. doi: 10.1016/j.jtho.2015.09.010. PubMed DOI

Yu J, Zhuang A, Gu X, Hua Y, Yang L, Ge S, et al. . Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. Cell Discovery (2023) 9:33. doi: 10.1038/s41421-023-00521-7. PubMed DOI PMC

Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. . Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun (2016) 7:12632. doi: 10.1038/ncomms12632. PubMed DOI PMC

Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, et al. . An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun (2017) 8:14369. doi: 10.1038/ncomms14369. PubMed DOI PMC

Chen D, Tan S, Zhang H, Wang H, He W, Shi R, et al. . The FG loop of PD-1 serves as a "Hotspot" for therapeutic monoclonal antibodies in tumor immune checkpoint therapy. iScience (2019) 14:113–24. doi: 10.1016/j.isci.2019.03.017. PubMed DOI PMC

Ludovini V, Bianconi F, Siggillino A, Vannucci J, Baglivo S, Berti V, et al. . High PD-L1/IDO-2 and PD-L2/IDO-1 co-expression levels are associated with worse overall survival in resected non-small cell lung cancer patients. Genes (Basel) (2021) 12(2):273. doi: 10.3390/genes12020273. PubMed DOI PMC

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252–64. doi: 10.1038/nrc3239. PubMed DOI PMC

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, et al. . Regulation of CTLA-4 expression during T cell activation. J Immunol (1996) 156:4154–9. doi: 10.4049/jimmunol.156.11.4154. PubMed DOI

Saijo H, Hirohashi Y, Honjo O, Saikai T, Shijubo N, Takabatake H, et al. . Anti-CTLA-4 antibody might be effective against non-small cell lung cancer with large size tumor. Anticancer Res (2023) 43:4155–60. doi: 10.21873/anticanres.16606. PubMed DOI

Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood (2018) 131:58–67. doi: 10.1182/blood-2017-06-741033. PubMed DOI PMC

Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 410:604–8. doi: 10.1038/35069112. PubMed DOI

De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The landscape of immunotherapy in advanced NSCLC: Driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines). Curr Oncol Rep (2021) 23:126. doi: 10.1007/s11912-021-01124-9. PubMed DOI PMC

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol (2016) 39:98–106. doi: 10.1097/COC.0000000000000239. PubMed DOI PMC

Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, et al. . CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: Diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother (2017) 66:1449–61. doi: 10.1007/s00262-017-2039-2. PubMed DOI PMC

Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 415:536–41. doi: 10.1038/415536a. PubMed DOI

Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms–genetics and function. Genes Immun (2011) 12:595–604. doi: 10.1038/gene.2011.75. PubMed DOI PMC

Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. . TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PloS One (2012) 7:e30676. doi: 10.1371/journal.pone.0030676. PubMed DOI PMC

Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev (2017) 276:97–111. doi: 10.1111/imr.12520. PubMed DOI PMC

Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. . Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol (2012) 137:978–85. doi: 10.1309/AJCP9Q6OVLVSHTMY. PubMed DOI

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, et al. . Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res (2019) 25:4663–73. doi: 10.1158/1078-0432.CCR-18-4142. PubMed DOI PMC

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, et al. . Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res (2018) 24:1816–23. doi: 10.1158/1078-0432.CCR-17-1922. PubMed DOI

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, et al. . LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J Thorac Oncol (2017) 12:814–23. doi: 10.1016/j.jtho.2017.01.019. PubMed DOI

Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett (2020) 20:207. doi: 10.3892/ol. PubMed DOI PMC

Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. . Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell (2019) 176:334–347.e12. doi: 10.1016/j.cell.2018.11.010 PubMed DOI PMC

Seager R, Senosain M-F, Roey EV, Gao S, DePietro P, Nesline MK, et al. . LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer. J Clin Oncol (2023) 41:e21113–3. doi: 10.1200/JCO.2023.41.16_suppl.e21113. DOI

Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B (2020) 10:414–33. doi: 10.1016/j.apsb.2019.08.010. PubMed DOI PMC

Kashima J, Okuma Y, Hosomi Y, Hishima T. High serum OX40 and OX40 ligand (OX40L) levels correlate with reduced survival in patients with advanced lung adenocarcinoma. Oncology (2020) 98:303–10. doi: 10.1159/000505975. PubMed DOI

Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, et al. . High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer (2019) 7:351. doi: 10.1186/s40425-019-0827-2. PubMed DOI PMC

Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. . The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol (2009) 10:48–57. doi: 10.1038/ni.1674. PubMed DOI

Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer (2020) 8(2):e000957. doi: 10.1136/jitc-2020-000957. PubMed DOI PMC

Patel AJ, Middleton GW. TIGIT-based immunotherapeutics in lung cancer. Immunother Adv (2023)3:ltad009. doi: 10.1093/immadv/ltad009. PubMed DOI PMC

Chen ZQ, Huang LS, Zhu B. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers (2018) 2018:9845123. doi: 10.1155/2018/9845123. PubMed DOI PMC

Ottonello S, Genova C, Cossu I, Fontana V, Rijavec E, Rossi G, et al. . Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol (2020) 11:125. doi: 10.3389/fimmu.2020.00125. PubMed DOI PMC

Zhao Y, Shi F, Zhou Q, Li Y, Wu J, Wang R, et al. . Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma. Med (Baltimore) (2020) 99:e23172. doi: 10.1097/MD.0000000000023172. PubMed DOI PMC

Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, et al. . Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget (2016) 7:56233–40. doi: 10.18632/oncotarget.v7i35. PubMed DOI PMC

Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, et al. . Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients. Front Immunol (2021) 12:665133. doi: 10.3389/fimmu.2021.665133. PubMed DOI PMC

Valadez-Cosmes P, Maitz K, Kindler O, Raftopoulou S, Kienzl M, Santiso A, et al. . Identification of novel low-density neutrophil markers through unbiased high-dimensional flow cytometry screening in non-small cell lung cancer patients. Front Immunol (2021) 12:703846. doi: 10.3389/fimmu.2021.703846. PubMed DOI PMC

Niki M, Yokoi T, Kurata T, Nomura S. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl) (2017) 8:91–9. doi: 10.2147/LCTT. PubMed DOI PMC

Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer (2014) 83:97–101. doi: 10.1016/j.lungcan.2013.08.020. PubMed DOI

Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, et al. . Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol (2015) 3:197–201. doi: 10.3892/mco.2014.436. PubMed DOI PMC

Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 8:5379–87. PubMed PMC

Peng Y, Zhang C, Rui Z, Tang W, Xu Y, Tao X, et al. . A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer. J Clin Lab Anal (2022) 36:e24224. doi: 10.1002/jcla.24224. PubMed DOI PMC

Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer. Front Immunol (2022) 13:827921. doi: 10.3389/fimmu.2022.827921. PubMed DOI PMC

He Y, Wang Y, Zhao S, Zhao C, Zhou C, Hirsch FR. sLAG-3 in non-small-cell lung cancer patients' serum. Onco Targets Ther (2018) 11:4781–4. doi: 10.2147/OTT. PubMed DOI PMC

Kim DH, Kim H, Choi YJ, Kim SY, Lee JE, Sung KJ, et al. . Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med (2019) 51:1–13. doi: 10.1038/s12276-019-0295-2. PubMed DOI PMC

Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. . Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell (2019) 177:414–427.e13. doi: 10.1016/j.cell.2019.02.016 PubMed DOI PMC

Xiong W, Gao Y, Wei W, Zhang J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer (2021) 7:837–46. doi: 10.1016/j.trecan.2021.03.003. PubMed DOI

Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, et al. . Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep (2016) 6:28910. doi: 10.1038/srep28910. PubMed DOI PMC

Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, et al. . Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol (2018) 57:1225–31. doi: 10.1080/0284186X.2018.1465585. PubMed DOI

Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers (2016) 2016:9085195. doi: 10.1155/2016/9085195. PubMed DOI PMC

Shi K, Liu T, Fu H, Li W, Zheng X. Genome-wide analysis of lncRNA stability in human. PloS Comput Biol (2021) 17:e1008918. doi: 10.1371/journal.pcbi.1008918. PubMed DOI PMC

Kazandjian D, Khozin S, Blumenthal G, Zhang L, Tang S, Libeg M, et al. . Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: A report from the US food and drug administration. JAMA Oncol (2016) 2:118–22. doi: 10.1001/jamaoncol.2015.3934. PubMed DOI

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. . Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer (2018) 115:71–4. doi: 10.1016/j.lungcan.2017.11.019. PubMed DOI

Morimoto K, Yamada T, Takumi C, Ogura Y, Takeda T, Onoi K, et al. . Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: A retrospective study. Front Oncol (2021) 11:630136. doi: 10.3389/fonc.2021.630136. PubMed DOI PMC

Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol (2018) 18:153–67. doi: 10.1038/nri.2017.108. PubMed DOI

Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity (2016) 44:1069–78. doi: 10.1016/j.immuni.2016.04.023. PubMed DOI

Muñoz-Unceta N, Burgueño I, Jiménez E, Paz-Ares L. Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2018) 10:1758835918804151. doi: 10.1177/1758835918804151. PubMed DOI PMC

Grote HJ, Feng Z, Schlichting M, Helwig C, Ruisi M, Jin HL, et al. . Programmed death-ligand 1 immunohistochemistry assay comparison studies in NSCLC: Characterization of the 73-10 assay. J Thorac Oncol (2020) 15:1306–16. doi: 10.1016/j.jtho.2020.04.013. PubMed DOI

Sun R, Kim AMJ, Lim SO. Glycosylation of immune receptors in cancer. Cells (2021) 10(5):1100. doi: 10.3390/cells10051100. PubMed DOI PMC

Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. . Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell (2019) 36:168–178.e4. doi: 10.1016/j.ccell.2019.06.008. PubMed DOI PMC

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. . Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol (2023) 41:1213–27. doi: 10.1200/JCO.22.00975. PubMed DOI PMC

Cui P, Li R, Huang Z, Wu Z, Tao H, Zhang S, et al. . Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC. Sci Rep (2020) 10:13160. doi: 10.1038/s41598-020-70207-7. PubMed DOI PMC

Wang H, Liu F, Chen X, Zhao C, Li X, Zhou C, et al. . Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol (2023) 12:56. doi: 10.1186/s40164-023-00412-3. PubMed DOI PMC

Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. . Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci USA (2020) 117:6640–50. doi: 10.1073/pnas.1921445117. PubMed DOI PMC

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, et al. . Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med (2018) 6:771–81. doi: 10.1016/S2213-2600(18)30284-4. PubMed DOI

Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs (2017) 9:182–212. doi: 10.1080/19420862.2016.1268307. PubMed DOI PMC

Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, et al. . CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1. Oncotarget (2017) 8:57964–80. doi: 10.18632/oncotarget.v8i35. PubMed DOI PMC

Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, et al. . A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun (2021) 12:4445. doi: 10.1038/s41467-021-24767-5. PubMed DOI PMC

Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol (2017) 8:1603. doi: 10.3389/fimmu.2017.01603. PubMed DOI PMC

Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, et al. . Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery (2017) 3:17004. doi: 10.1038/celldisc.2017.4. PubMed DOI PMC

Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, et al. . CX-072 (pacmilimab), a probody. J Immunother Cancer (2021) 9(7):e002447. doi: 10.1136/jitc-2021-002447. PubMed DOI PMC

Giesen D, Broer LN, Lub-de Hooge MN, Popova I, Howng B, Nguyen M, et al. . Probody therapeutic design of. Clin Cancer Res (2020) 26:3999–4009. doi: 10.1158/1078-0432.CCR-19-3137. PubMed DOI

Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, et al. . Conditional PD-1/PD-L1 probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti-PD-1/PD-L1 agents. Cancer Immunol Res (2021) 9:1451–64. doi: 10.1158/2326-6066.CIR-21-0031. PubMed DOI PMC

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation therapeutics. Annu Rev Pharmacol Toxicol (2020) 60:391–415. doi: 10.1146/annurev-pharmtox-010818-021118. PubMed DOI

Rubins DJ, Meng X, McQuade P, Klimas M, Getty K, Lin SA, et al. . In vivo evaluation and dosimetry estimate for a high affinity affibody PET tracer targeting PD-L1. Mol Imaging Biol (2021) 23:241–9. doi: 10.1007/s11307-020-01544-2. PubMed DOI

Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discovery Today (2008) 13:695–701. doi: 10.1016/j.drudis.2008.04.013. PubMed DOI

Foord E, Klynning C, Schoutrop E, Förster JM, Krieg J, Mörtberg A, et al. . Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin® Proteins. J Immunol Res (2020) 2020:7375947. doi: 10.1155/2020/7375947. PubMed DOI PMC

Binz HK, Bakker TR, Phillips DJ, Cornelius A, Zitt C, Göttler T, et al. . Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate. MAbs (2017) 9:1262–9. doi: 10.1080/19420862.2017.1305529. PubMed DOI PMC